RX Biosyent Inc

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) today released a summary of its
Third Quarter (Q3) 2011 financial results.


Total Sales for Q3 2011, hit a new record and were 60% higher at $983,857
compared to $616,964 in the corresponding prior year period. The pharmaceutical
business sales grew 215% from $191,716 in Q3 2010 to $604,523 in Q3 2011.


Total Sales for the nine months ending September 30, 2011 were 73% higher at
$2,105,329 compared to $1,216,019 in the prior year period. In the nine months
ending September 30, 2011, sales in the pharmaceutical business were $1,392,334,
demonstrating growth of 225% over the prior year period sales at $427,977. Over
the last 6 quarters the compounded quarterly growth in the company's
pharmaceutical business has averaged 40%.


The Company earned total comprehensive income of $235,998 in Q3 2011, which was
85% higher than the total comprehensive income for Q3 2010 of $127,389. In the
nine months ending September 30, 2011, the Company earned comprehensive income
of $349,452 compared to a comprehensive loss of ($31,987) in the nine months
ending September 30, 2010.


Total cash flow for the nine months ending September 30, 2011, was $355,830
versus a negative cash flow of ($3,646) in the prior year period.


Full details of Q3 2011 results including Sept 30, 2011 Financial Statements and
Management's Discussion & Analysis will be posted on sedar.com on November 15,
2011.


BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source
products that have been successfully developed and proven to be safe and
effective; manage these products through the regulatory process and product
registration (approval); and once approved, market these products in Canada. The
Company is focused on medications that occupy a niche in the market, that are
unique either due to complexity of manufacture or provide novel technological or
therapeutic advantages, or that are backed by strong partners holding
intellectual property rights that are defendable. This strategy allows the
Company to market these medications as brands owned by, or licensed to, it.


BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly
owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences
pharmaceutical products and markets these products in Canada. Wholly owned
BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy
business marketing bio and health friendly non-chemical insecticides. BioSyent
common shares are listed for trading on the TSX Venture Exchange (TSXV) under
the symbol RX.


This press release may contain information or statements that are
forward-looking. The contents herein represent our judgment, as at the release
date, and are subject to risks and uncertainties that may cause actual results
or outcomes to be materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future revenue,
operations, profitability and obtaining regulatory approvals.

Biosyent (TSXV:RX)
Historical Stock Chart
From May 2024 to Jun 2024

Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2023 to Jun 2024